Skip to content
Abierto
Menu

Award notice

Development of the Actinide Decorporation Agent HOPO-101 for Broad Spectrum Heavy Metal Exposure

75A50124C00062

Office of Assistant Secretary for Preparedness and Response, Barda - Aspr / Daappo / Barda DCMA. Research and Development in Biotechnology (except Nanobiotechnology).

View on SAM.govMarkdown

Awarded

Hopo Therapeutics, Inc.

$226,309,811.00 on the award notice, September 30, 2024, contract 75A50124C00062

Description

As published on SAM.gov.

This contract was awarded as a Cost Contract based on the research and development nature of the contract. Dueto the uncertainties involved in the contract performance related to the requirements, the Government is not able to estimate with sufficient accuracy the level of efforts or costs for the work.

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Hopo Therapeutics, Inc.
UEI
H5MWN5ZBXQ98
CAGE
8L3L6
Vendor location
Berkeley, CA
Contract
75A50124C00062, definitive contract
Obligated
$14,209,253.00, potential $231,149,540
Actions
5 between September 27, 2024 and April 27, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Development of Hopo-101 as an MCM (Medical Countermeasure) Decorporation Agent for the Treatment of Individuals with Known or Suspected Internal Contamination with Radionuclides (The ?mcm Indication?) And/Or Toxic Heavy Metals of Interest for Commerc
Match
award number 75A50124C00062 equals the contract number; same awarding office 75A501 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. October 7, 2024

    Award notice, originally solicitation

    Awarded to HOPO THERAPEUTICS, Inc. Berkeley for $226,309,811. SAM.gov, notice c6d8ccb4744341f18ceae2f5c3e04bdc

Points of contact

Also open from this buyer